Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.35USD
6:21pm BST
Change (% chg)

$-0.14 (-5.62%)
Prev Close
$2.49
Open
$2.41
Day's High
$2.41
Day's Low
$2.35
Volume
3,172
Avg. Vol
29,083
52-wk High
$5.55
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED.ONCOMED PHARMACEUTICALS INC - IN INTERIM, OFFICE OF PRESIDENT WILL CONTINUE TO PERFORM DUTIES OF PRESIDENT AND CEO.ONCOMED PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED PERRY KARSEN AS CHAIRMAN OF BOARD.  Full Article

OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM.ONCOMED PHARMACEUTICALS INC - YEAR-END 2017 CASH BALANCE OF $103.1 MILLION.ONCOMED PHARMACEUTICALS INC - ‍PRESENTATION OF CLINICAL DATA ON PHASE 1 PROGRAMS EXPECTED IN 2018​.ONCOMED PHARMACEUTICALS - CURRENT CASH ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 2019.ONCOMED - ESTIMATES 2018 OPERATING CASH BURN TO BE LESS THAN $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS.ONCOMED - ‍TO INITIATE PHASE 1B PORTION OF ITS ANTI-TIGIT TRIAL TO STUDY ANTI-TIGIT IN COMBINATION WITH ANTI-PD1 IN FIRST HALF OF 2018​.  Full Article

Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - PERCEPTIVE ADVISORS LLC :PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC <<>>AS OF NOV 6 - SEC FILING.  Full Article

Oncomed posts Q3 loss per share $0.28
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article

BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing
Friday, 26 Aug 2016 

BVF Inc:BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

OncoMed Pharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 

OncoMed Pharmaceuticals Inc : OncoMed Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.50 million common shares priced at $10.00 per share.  Full Article

Oncomed Pharmaceuticals announces proposed public offering of common stock
Wednesday, 17 Aug 2016 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces proposed public offering of common stock .To use net proceeds from offering for general corporate purposes, increasing working capital, funding research development.  Full Article

Oncomed pharmaceuticals reports Q2 2016 financial results
Tuesday, 9 Aug 2016 

Oncomed Pharmaceuticals Inc : Oncomed pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.91.  Full Article

BRIEF-Oncomed Reports Q1 Loss Per Share $0.15

* ONCOMED ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS